Page last updated: 2024-12-09

1-(4-methoxyphenyl)-3-(2-methyl-1,3-benzoxazol-5-yl)urea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-(4-methoxyphenyl)-3-(2-methyl-1,3-benzoxazol-5-yl)urea is a synthetic compound with a complex chemical structure. While the exact purpose and importance of this specific compound are not readily available in public databases, we can deduce its potential significance based on its structure and related compounds.

**Structure Analysis:**

* **Urea moiety:** The central urea group (NH-CO-NH) is a common functional group in many drugs and biological molecules. It can participate in hydrogen bonding, which plays a crucial role in interactions with biomolecules.
* **Methoxyphenyl group:** The presence of a methoxy group (OCH3) attached to a phenyl ring suggests potential for interactions with biological targets due to its hydrophobic and electron-donating properties.
* **Benzoxazole ring:** Benzoxazole rings are often found in compounds with pharmacological activity, particularly those targeting the central nervous system. The methyl group on the benzoxazole ring could modulate its activity or enhance its solubility.

**Potential Importance for Research:**

Given its structure, 1-(4-methoxyphenyl)-3-(2-methyl-1,3-benzoxazol-5-yl)urea might be investigated for:

* **Pharmacological activity:** The compound could potentially exhibit biological activity due to its structural features. This could be explored in various areas like:
* **Antimicrobial activity:** Many compounds with benzoxazole rings exhibit antimicrobial activity against bacteria and fungi.
* **Anti-inflammatory activity:** The compound might interact with inflammatory pathways.
* **Neuroprotective effects:** Benzoxazole derivatives have been shown to possess neuroprotective properties.
* **Chemical probes:** The compound could serve as a chemical probe to study the interactions of other molecules with specific proteins or enzymes.
* **Materials science:** The compound's structure might allow for the synthesis of polymers or other materials with unique properties.

**Note:** It is crucial to understand that the information provided above is based on general knowledge and analysis of the compound's structure. To know the exact importance and specific research areas where this compound is being studied, one needs to consult specialized scientific databases and literature on specific research projects.

Cross-References

ID SourceID
PubMed CID894044
CHEMBL ID1569574
CHEBI ID121694

Synonyms (12)

Synonym
HMS2589J04
MLS000708699 ,
smr000289266
AH-487/41957482
n-(4-methoxyphenyl)-n'-(2-methyl-1,3-benzoxazol-5-yl)urea
CHEBI:121694
AKOS000603012
1-(4-methoxyphenyl)-3-(2-methyl-1,3-benzoxazol-5-yl)urea
CHEMBL1569574
bdbm60140
cid_894044
Q27210259
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
ureas
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.19950.003245.467312,589.2998AID2517
LuciferasePhotinus pyralis (common eastern firefly)Potency11.99550.007215.758889.3584AID588342
BRCA1Homo sapiens (human)Potency2.81840.89137.722525.1189AID624202
ATAD5 protein, partialHomo sapiens (human)Potency17.35120.004110.890331.5287AID504466; AID504467
thioredoxin glutathione reductaseSchistosoma mansoniPotency50.11870.100022.9075100.0000AID485364
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency5.80480.00419.984825.9290AID504444
ras-related protein Rab-9AHomo sapiens (human)Potency3.54810.00022.621531.4954AID485297
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
lamin isoform A-delta10Homo sapiens (human)Potency7.94330.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
M17 leucyl aminopeptidasePlasmodium falciparum 3D7IC50 (µMol)14.81001.000027.8360138.0800AID1619
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]